ArticleThe Journal of infectious diseases2019
Development of a Rhinovirus Inoculum Using a Reverse Genetics Approach.
Article in The Journal of infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 9 citations in OpenAlex.
- Monopoly of Minor Group Rhinovirus Infections in Hospitalised Children in Hong Kong During the SARS-CoV-2 Pandemic.Viruses · 2025Article
- Risk analysis for outpatient experimental infection as a pathway for affordable RSV vaccine development.NPJ vaccines · 2025Article
- Construction and characterization of an infectious cDNA clone of human rhinovirus A89.Heliyon · 2024Article
- Assessing immune factors in maternal milk and paired infant plasma antibody binding to human rhinoviruses.Frontiers in immunology · 2024Article
- Epithelial cell responses to rhinovirus identify an early-life-onset asthma phenotype in adults.The Journal of allergy and clinical immunology · 2022Article
- Enhanced Neutralizing Antibody Responses to Rhinovirus C and Age-Dependent Patterns of Infection.American journal of respiratory and critical care medicine · 2021Article
- Reverse Genetics and Rhinovirus-A New Approach to an Old Problem?The Journal of infectious diseases · 2019Article
Corrections and comments
- Commented on by
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundExperimental inoculation is an important tool for common cold and asthma research. Producing rhinovirus (RV) inocula from nasal secretions has required prolonged observation of the virus donor to exclude extraneous pathogens. We produced a RV-A16 inoculum using reverse genetics and determined the dose necessary to cause moderate colds in seronegative volunteers.
methodsThe consensus sequence of RV-A16 from a previous inoculum was cloned, and inoculum virus was produced using reverse genetics techniques. After safety testing, volunteers were inoculated with either RV-A16 (n = 26) or placebo (n = 10), Jackson cold scores were recorded, and nasal secretions were tested for shedding of RV-A16 ribonucleic acid.
resultsThe reverse genetics process produced infectious virus that was neutralized by specific antisera and had a mutation rate similar to conventional virus growth techniques. The 1000 median tissue culture infectious dose (TCID50) dose produced moderate colds in most individuals with effects similar to that of a previously tested conventional RV-A16 inoculum.
conclusionsReverse genetics techniques produced a RV-A16 inoculum that can cause clinical colds in seronegative volunteers, and they also serve as a stable source of virus for laboratory use. The recombinant production procedures eliminate the need to derive seed virus from nasal secretions, thus precluding introduction of extraneous pathogens through this route.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.